V BRYAN LAWLIS
CIK 1247681 · last filed 2025-05-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.23M
Companies
6
Total Filings
81
Lifetime Open-Market Net
-$9.50M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GERN | Director | 13,300 | $1.57 | $20.9K | -$220.6K | 16 | 2025-05-22 |
| BMRN | Director | 33,140 | $66.53 | $2.20M | -$9.28M | 45 | 2023-05-24 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 5 | 2022-06-09 |
| CHRS | Director | — | $1.42 | — | $0 | 10 | 2021-01-13 |
| STRO | Director | — | $20.07 | — | $0 | 1 | 2018-09-27 |
| HUMANIGEN, INC (KBIO) Delisted | Director | — | — | — | $0 | 1 | 2013-09-03 |
Recent Filings · Page 2 of 9
81 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-04-04 | BMRN | Mixed | — | -$248.9K | EDGAR |
| 2022-06-09 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-26 | BMRN | Grant (A) | +4,980 | $0 | EDGAR |
| 2022-05-11 | GERN | Grant (A) | — | $0 | EDGAR |
| 2022-04-18 | BMRN | Mixed | — | -$196.3K | EDGAR |
| 2022-01-19 | BMRN | Mixed | — | -$213.1K | EDGAR |
| 2021-06-09 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-27 | BMRN | Grant (A) | +5,120 | $0 | EDGAR |
| 2021-05-13 | GERN | Grant (A) | — | $0 | EDGAR |
| 2021-04-19 | BMRN | Mixed | — | -$378.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.